Edwards Lifesciences — Feb 11, 2025 release

The company expects to maintain R&D spending at these levels during 2025, and to moderate R&D as a percentage of sales over time. Operating profit margin in the fourth quarter of 22.6%, or 25.6% adjusted, was in-line with the company’s expectation for the quarter. Edwards’ guidance for 2025 adjusted operating margins continues to be 27 to 28% with annual operating profit margin expansion thereafter, as outlined at the company’s investor conference. Edwards' adjusted Earnings Per Share was $0.59, led by strong top-line performance. Cash and cash equivalents were approximately $3.0 billion as of Dec. 31, 2024. Total debt was approximately $600 million. Outlook Edwards' full-year total company and product group sales guidance as well as earnings guidance remain unchanged. For the first quarter of 2025, the company projects total sales to be between $1.35 and $1.43 billion and adjusted EPS of $0.58 to $0.64. About Edwards Lifesciences      Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube. 3 Conference Call and Webcast Information      The company will be hosting a conference call today at 2:00 p.m. PT to discuss its fou